ABOUT Concord Biotech
- Industry -
- ISIN INE338H01029
- BSE Code 543960
- NSE Code CONCORDBIO
Concord Biotech Limited is an India-based research and development driven biopharma company. The Company is engaged in the research and development, manufacturing, marketing, and selling of pharmaceutical products. The Company manufactures active pharmaceutical ingredients (API) through fermentation and semi-synthetic processes and finished formulations. It manufactures fermentation and semi-synthetic based products in the therapeutic segments, such as immunosuppressants, anti-bacterial, oncology, anti-fungal and others. Its API products include Mycophenolate Mofetil, Mycophenolate Sodium, Cyclosporine, Vancomycin Hydrochloride, Micafungin Sodium, Mupirocin, Romidepsin, Dactinomycin, and Pravastatin Sodium, among others. It also has a pipeline of API products under development. Its API products under development include Polymyxin B, Fidaxomicin, Doxorubicin, and others. The Company provides products in the critical care, immunology, nephrology, and transplant medicine segments.
Concord Biotech Management
- Sudhir Vaid Executive Chairman of the Board, Managing Director
- Ankur Vaid Chief Executive Officer, Joint Managing Director, Executive Director
- Lalit Sethi Chief Financial Officer
- Prakash Sajnani Compliance Officer, Company Secretary, Assistant Vice President - Finance
- Devang Bhatt Vice President - Sales and Marketing, Head - Limbasi Plant - 3
- Manoj Kumar Vice-President - Formulation Division and Head - Valthera Unit - 2
- Sundeep Bengani General Manager - International Business Development, Formulation Division
You have to be logged in to add this to Watchlist.